# US 2004/0063164 A1 · Kit and method for detecting the esm-1 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063164 A1
- Document ID: US20040063164A1
- Status: Published application
- Kind: A1
- Application number: 10/416,204
- Filed: 2003-10-21
- Published: 2004-04-01
- Earliest claimed: 2000-11-09
- Assignees: Institut Pasteur de Lille; Institut National de la Sante et de la Recherche Medicale
- Inventors: Philippe Lassalle; David Bechard; Andre-Bernard Tonnel
- Web page: https://patentgrep.com/patent/US20040063164A1

## CPC

- C07K 16/18: against material from animals or humans
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- Y10S 435/975: Kit
- Y10S 436/811: Test for named disease, body condition or organ function
- Y10S 436/813: Cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in pos4ition 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.

## Claims

### Claim 1

Kit for the detection of protein ESM-1 in a sample, comprising:
a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and
b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.

### Claim 2 (depends on 1)

Kit for detection according to claim 1, characterized in that the antibody specifically binding to the N-terminal region of protein ESM-1 has been obtained by immunization of a mammal with recombinant protein ESM-1 produced by a eukaryotic cell.

### Claim 3 (depends on 1, 2)

Kit for detection according one of claims 1 and 2, characterized in that the antibody specifically binding to the N-terminal region of protein ESM-1 is the monoclonal antibody produced by the hybridoma line designated MEC 15 deposited at the Collection de Cultures de Micro-organismes (CNCM) of the Institut Pasteur on Oct. 17, 2000 under the access number I-2572.

### Claim 4 (depends on 1, 2, 3)

Kit for detection according to one of claims 1 to 3, characterized in that the antibody specifically binding to the C-terminal region of ESM-1 is chosen from among the antibodies able to recognize one of the three following antigenic determinants:
a) the determinant AgD1 running from the proline residue in position 79 up to the cysteine residue in position 99 of ESM-1,
b) the antigenic determinant AgD2 running from the serine residue in position 119 up to the valine residue in position 139 of protein ESM-1;
c) the antigenic determinant AgD3 running from the glycine residue in position 159 up to the arginine residue in position 184 of protein ESM-1.

### Claim 5 (depends on 4)

Kit for detection according to claim 4, characterized in that the antibody specifically binding to the C-terminal region of protein ESM-1 is chosen from among the following antibodies:
a) the antibody MEP 21 produced by the hybridoma line deposited at the CNCM on Nov. 19, 1997 under the access number I-1944;
b) the monoclonal antibody MEP08 produced by the hybridoma line deposited on Nov. 19, 1997 at the CNCM under the access number I-1941;
c) the monoclonal antibody MEP14 produced by the hybridoma line deposited on Nov. 19, 1997 at the CNCM under the access number I-1942;
d) the monoclonal antibody MEP19 produced by the hybridoma line deposited on Nov. 19, 1997 at the CNCM under the access number I-1943.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Kit for detection according to one of claims 1 to 5, characterized in that at least one of the two antibodies is covalently linked to a molecule enabling its direct or indirect detection.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

Kit for detection according to one of claims 1 to 6, characterized in that the first or the second antibody is immobilized on a support.

### Claim 8 (depends on 7)

Kit for detection according to claim 7, characterized in that the antibody immobilized on a support is the antibody specifically recognizing the C-terminal region of protein ESM-1.

### Claim 9

Method for detecting protein ESM-1 in a sample, characterized in that it comprises the following steps:
a) placing the sample to be tested in contact with a first antibody specifically binding to the N-terminal region of protein ESM-1 or with a first antibody binding to the C-terminal region of protein ESM-1;
b) placing the complex potentially formed between the protein ESM-1 present in the sample and the first antibody in contact with a second antibody specifically binding to the region of protein ESM-1, chosen from the N-terminal region or the C-terminal region, not recognized by the first antibody; and
c) detecting the complex formed between protein ESM-1 and the second antibody.

### Claim 10 (depends on 9)

Method of detection according to claim 9, characterized in that the first antibody is immobilized on a support.

### Claim 11 (depends on 9, 10)

Method of detection according to on of claims 9 and 10, characterized in that the first antibody is an antibody specifically binding to the C-terminal region of protein ESM-1 and the second antibody is an antibody specifically binding to the N-terminal region of protein ESM-1.

### Claim 12 (depends on 9, 10, 11)

Method of detection according to any one of claims 9 to 11, characterized in that the antibody specifically binding to the N-terminal region of protein ESM-1 is the antibody MEC15 produced by the hybridoma deposited on Oct. 17, 2000 at the CNCM under the access number I-2572.

### Claim 13 (depends on 9, 10, 11, 12)

Method of detection according to any one of claims 9 to 12, characterized in that step c) is performed using a biotinylated antibody able to fix to the second antibody.

### Claim 14

Hybridoma line MEC15 deposited at the CNCM on Nov. 19, 1997 under the number noI-1942.

### Claim 15

Monoclonal antibody produced by the hybridoma line MEC15 deposited on Oct. 17, 2000 at the CNCM under the access number I-2572.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Use of a detection kit according to any one of claims 1 to 8 to detect in vitro deteriorations to the endothelial vascular wall in humans.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Use of a detection kit according to any one of claims 1 to 8 for the quantification of protein ESM-1 in vitro in a patient treated with an immunosuppressant compound.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Use of a detection kit according to any one of claims 1 to 8 for the quantification in vitro of protein ESM-1 in a patient suffering from cancer.
